Outcomes of Expanded Autologous Bone Marrow-derived Mesenchymal Stem Cells Therapy in Type II Diabetes

Outcomes of Expanded Autologous Bone Marrow-derived Mesenchymal Stem Cells Therapy in Type 2 Diabetes

The purpose of this study is to evaluate the safety and effectiveness of autologous bone marrow-derived mesenchymal stem cells transplantation in the treatment of type 2 diabetes mellitus

Bone marrow-derived mesenchymal stem cells have the immunosuppressive effect and secrete a variety of cytokines, improve the microenvironment of diabetic patients, targeting insulin resistance tissue, ameliorate the metabolic disorder of islet damage, protect and regeneration of the islet beta cells; reduce high blood sugar.The purpose of this study is to evaluate the safety and effectiveness of autologous bone marrow-derived mesenchymal stem cells transplantation in treatment 30 patients with type 2 diabetes mellitus at Vinmec International Hospital, Hanoi, Vietnam

Inclusion Criteria:

• Males and females
• Age from 18 years and above.
• Hemoglobin A1c (HbA1c) is ranged from 7.5% to 9% at baseline.
• Type 2 diabetes duration 5 years or more.
• Before the screening, joint or combined with insulin, oral medications to treat more than 3 months.
• Who signed the informed consent form.

Exclusion Criteria:

• Type 1 diabetes.
• Chronic disease or severe disease, including cancer, severe heart disease, kidney disease, liver disease, etc.
• According to the medical doctor's judgement, may endanger the safety of the subjects